Crosstalk between autophagy and apoptosis in initiating antitumor immune responses in human lymphoma cells
Exploration of Immunology · 11.09.2025 · 5
DOI: 10.37349/ei.2025.1003216 ↗Kurz gefasst
Fachartikel in der Zeitschrift Exploration of Immunology, online erschienen am 11.09.2025. Verfasst von Kayce Blumenstock und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA.
Abstract (Originalsprache)
Aim
Despite advances in lymphoma treatment, resistance to conventional therapies and insufficient immune-mediated tumor clearance remain major challenges. This study investigates the dual antitumor mechanisms of the mushroom-derived triterpenoid, ganoderic acid DM (GA-DM), exploring its ability to induce programmed cell death while enhancing immune recognition in diffuse large B-cell lymphoma (DLBCL).
Methods
DLBCL cells (DB and Toledo) were treated with GA-DM (0–40 μM), and cell viability was assessed via MTS assay. Apoptosis was evaluated through caspase-3 activation and inhibition by ZVAD-FMK, while autophagy was measured via LC3 protein expression. Flow cytometry analyzed HLA class II surface expression and antigen presentation to CD4+ T cells (via IL-2 production), with autophagy’s role further confirmed using the inhibitor 3-MA.
Results
GA-DM exhibited potent and dose-dependent cytotoxicity against DLBCL cells, with concentrations of 30–40 μM inducing over 60% cell death within 24 h. Mechanistic studies revealed that GA-DM activated the intrinsic apoptotic pathway, as evidenced by caspase-3 cleavage and the significant reduction in cell death upon ZVAD-FMK treatment. Concurrently, GA-DM treatment upregulated the autophagy marker LC3-II, indicating the induction of autophagy. Strikingly, GA-DM also enhanced the immunogenicity of lymphoma cells by increasing surface expression of HLA class II molecules. This led to improved antigen presentation and subsequent activation of CD4+ T cells, as demonstrated by a 2.5-fold increase in IL-2 production (amount of IL-2 in pg/mL) compared to untreated controls. The critical role of autophagy in this process was confirmed by the near-complete abrogation of HLA class II-mediated T-cell activation upon 3-MA treatment.
Conclusions
GA-DM synergistically induces apoptosis and autophagy while promoting immune-mediated tumor clearance through enhanced HLA class II antigen presentation. These findings highlight GA-DM as a promising multi-modal therapeutic candidate for lymphoma immunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA.
- Ralph H. Johnson Veterans Administration Medical Center, Charleston, SC 29401, USA.
- Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
- Department of Neurosurgery, Medical University of South Carolina, Charleston, SC 29425, USA.
ORCID-Profile: Kayce Blumenstock, Faisal F Y Radwan, Vandana Zaman, Narendra L Banik, Azizul Haque
Förderung
- BLRD VA
Zitieren
APA
Blumenstock, K., Radwan, F. F. Y., Zaman, V., Banik, N. L., & Haque, A. (2025). Crosstalk between autophagy and apoptosis in initiating antitumor immune responses in human lymphoma cells. Exploration of Immunology, 5. https://doi.org/10.37349/ei.2025.1003216
Vancouver
Blumenstock K, Radwan FFY, Zaman V, Banik NL, Haque A. Crosstalk between autophagy and apoptosis in initiating antitumor immune responses in human lymphoma cells. Exploration of Immunology. 2025;5. doi:10.37349/ei.2025.1003216
BibTeX
@article{Blumenstock2025,
author = {Blumenstock, Kayce and Radwan, Faisal F Y and Zaman, Vandana and Banik, Narendra L and Haque, Azizul},
title = {Crosstalk between autophagy and apoptosis in initiating antitumor immune responses in human lymphoma cells},
journal = {Exploration of Immunology},
year = {2025},
volume = {5},
doi = {10.37349/ei.2025.1003216}
}
EUVIMED